Hjem › Diffust stort B-celle lymfom › Indiana
Diffust stort B-celle lymfom kliniske forsøg i Indiana
9 studier for Diffust stort B-celle lymfom søger deltagere på steder i Indiana.
Byer i Indiana
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- IU Simon Comprehensive Cancer Center, Indianapolis
- Indiana Blood and Marrow Transplantation, Indianapolis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Northwest Cancer Center - Crown Point, Crown Point
- Northwest Oncology LLC, Dyer
- Saint Mary Medical Center, Hobart
- og 4 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06649812A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- St Vincent Ascension at Peyton Manning Childrens Hospital, Indianapolis
- Investigative Clinical Research of Indiana, Noblesville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06091865Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Indiana Blood and Marrow Transplantation, Indianapolis
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 10. jul. 2026 · NCT05852717Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- Northwest Cancer Center - Hobart, Hobart
- og 5 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. okt. 2025 · NCT05890352DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. apr. 2023 · NCT04920617Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Goshen Center for Cancer Care, Goshen
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2022 · NCT04502394Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.